Resverlogix announces publication on apabetalone in Clinical Epigenetics
Resverlogix announced the publication of an article titled: “Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism” in Clinical Epigenetics, a top tier, open access journal devoted to the study of epigenetics. July 15, 2019